341 related articles for article (PubMed ID: 31092862)
1. Determination and analysis of agonist and antagonist potential of naturally occurring flavonoids for estrogen receptor (ERα) by various parameters and molecular modelling approach.
Puranik NV; Srivastava P; Bhatt G; John Mary DJS; Limaye AM; Sivaraman J
Sci Rep; 2019 May; 9(1):7450. PubMed ID: 31092862
[TBL] [Abstract][Full Text] [Related]
2. Structural insights into Resveratrol's antagonist and partial agonist actions on estrogen receptor alpha.
Chakraborty S; Levenson AS; Biswas PK
BMC Struct Biol; 2013 Oct; 13():27. PubMed ID: 24160181
[TBL] [Abstract][Full Text] [Related]
3. Structural insights into selective agonist actions of tamoxifen on human estrogen receptor alpha.
Chakraborty S; Biswas PK
J Mol Model; 2014 Aug; 20(8):2338. PubMed ID: 25060147
[TBL] [Abstract][Full Text] [Related]
4. Phenytoin is an estrogen receptor α-selective modulator that interacts with helix 12.
Fadiel A; Song J; Tivon D; Hamza A; Cardozo T; Naftolin F
Reprod Sci; 2015 Feb; 22(2):146-55. PubMed ID: 25258361
[TBL] [Abstract][Full Text] [Related]
5. Estrogen receptor α L543A,L544A mutation changes antagonists to agonists, correlating with the ligand binding domain dimerization associated with DNA binding activity.
Arao Y; Hamilton KJ; Coons LA; Korach KS
J Biol Chem; 2013 Jul; 288(29):21105-21116. PubMed ID: 23733188
[TBL] [Abstract][Full Text] [Related]
6. Elucidation of Agonist and Antagonist Dynamic Binding Patterns in ER-α by Integration of Molecular Docking, Molecular Dynamics Simulations and Quantum Mechanical Calculations.
Sakkiah S; Selvaraj C; Guo W; Liu J; Ge W; Patterson TA; Hong H
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502280
[TBL] [Abstract][Full Text] [Related]
7. Structural insight into the antagonistic action of diarylheptanoid on human estrogen receptor alpha.
Geetha Rani Y; Lakshmi BS
J Biomol Struct Dyn; 2019 Mar; 37(5):1189-1203. PubMed ID: 29557271
[TBL] [Abstract][Full Text] [Related]
8. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells.
Marsaud V; Gougelet A; Maillard S; Renoir JM
Mol Endocrinol; 2003 Oct; 17(10):2013-27. PubMed ID: 12855746
[TBL] [Abstract][Full Text] [Related]
9. Baicalein has protective effects on the 17β-estradiol-induced transformation of breast epithelial cells.
Chen Y; Wang J; Hong DY; Chen L; Zhang YY; Xu YN; Pan D; Fu LY; Tao L; Luo H; Shen XC
Oncotarget; 2017 Feb; 8(6):10470-10484. PubMed ID: 28060756
[TBL] [Abstract][Full Text] [Related]
10. In silico identification of novel inhibitors targeting the DNA-binding domain of the human estrogen receptor alpha.
Cao H; Sun Y; Wang L; Pan Y; Li Z; Liang Y
J Steroid Biochem Mol Biol; 2021 Oct; 213():105966. PubMed ID: 34416373
[TBL] [Abstract][Full Text] [Related]
11. Simulations reveal increased fluctuations in estrogen receptor-alpha conformation upon antagonist binding.
Ng HL
J Mol Graph Model; 2016 Sep; 69():72-7. PubMed ID: 27580485
[TBL] [Abstract][Full Text] [Related]
12. Preliminary molecular dynamic simulations of the estrogen receptor alpha ligand binding domain from antagonist to apo.
McGee TD; Edwards J; Roitberg AE
Int J Environ Res Public Health; 2008 Jun; 5(2):111-4. PubMed ID: 18678925
[TBL] [Abstract][Full Text] [Related]
13. Conformational dynamics of the estrogen receptor alpha: molecular dynamics simulations of the influence of binding site structure on protein dynamics.
Celik L; Lund JD; Schiøtt B
Biochemistry; 2007 Feb; 46(7):1743-58. PubMed ID: 17249692
[TBL] [Abstract][Full Text] [Related]
14. Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists.
Barkhem T; Carlsson B; Nilsson Y; Enmark E; Gustafsson J; Nilsson S
Mol Pharmacol; 1998 Jul; 54(1):105-12. PubMed ID: 9658195
[TBL] [Abstract][Full Text] [Related]
15. Estrogen receptor beta activates the human retinoic acid receptor alpha-1 promoter in response to tamoxifen and other estrogen receptor antagonists, but not in response to estrogen.
Zou A; Marschke KB; Arnold KE; Berger EM; Fitzgerald P; Mais DE; Allegretto EA
Mol Endocrinol; 1999 Mar; 13(3):418-30. PubMed ID: 10076999
[TBL] [Abstract][Full Text] [Related]
16. Elucidating Binding Sites and Affinities of ERα Agonists and Antagonists to Human Alpha-Fetoprotein by In Silico Modeling and Point Mutagenesis.
Moldogazieva NT; Ostroverkhova DS; Kuzmich NN; Kadochnikov VV; Terentiev AA; Porozov YB
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32019136
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel natural compound inhibitors targeting estrogen receptor α by an integrated virtual screening strategy.
Yu E; Xu Y; Shi Y; Yu Q; Liu J; Xu L
J Mol Model; 2019 Aug; 25(9):278. PubMed ID: 31463793
[TBL] [Abstract][Full Text] [Related]
18. TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor alpha and a partial agonist on estrogen receptor beta with low uterotrophic effect.
Yamamoto Y; Shibata J; Yonekura K; Sato K; Hashimoto A; Aoyagi Y; Wierzba K; Yano S; Asao T; Buzdar AU; Terada T
Clin Cancer Res; 2005 Jan; 11(1):315-22. PubMed ID: 15671561
[TBL] [Abstract][Full Text] [Related]
19. Domains of estrogen receptor alpha (ERalpha) required for ERalpha/Sp1-mediated activation of GC-rich promoters by estrogens and antiestrogens in breast cancer cells.
Kim K; Thu N; Saville B; Safe S
Mol Endocrinol; 2003 May; 17(5):804-17. PubMed ID: 12576490
[TBL] [Abstract][Full Text] [Related]
20. In silico Molecular Modelling of Selected Natural Ligands and their Binding Features with Estrogen Receptor Alpha.
Maruthanila VL; Elancheran R; Roy NK; Bhattacharya A; Kunnumakkara AB; Kabilan S; Kotoky J
Curr Comput Aided Drug Des; 2019; 15(1):89-96. PubMed ID: 30306879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]